Pilot Study of Injection of OnabotulinumtoxinA Toward the Sphenopalatine Ganglion for the Treatment of Classical Trigeminal Neuralgia.

ABSTRACT:

Background

The sphenopalatine ganglion (SPG) has previously been targeted in trigeminal neuralgia (TN), but its role in this condition has not been established.

Objective

To investigate the safety of injecting onabotulinumtoxinA (BTA) toward the SPG using the MultiGuide^® in 10 patients with refractory classical TN, and collect preliminary efficacy data.

Methods

Twenty-five international units (IU) of BTA were injected toward the SPG in a prospective, open-label study in 10 patients with refractory classical TN. All patients were recruited and treated on an out-patient basis at St. Olav's University Hospital in Trondheim (Norway).

Primary outcome

adverse events (AEs). Primary efficacy outcome: number of TN attacks at weeks 5-8 after injection compared

SUBMITTER: Crespi J 

PROVIDER: S-EPMC6771650 | biostudies-literature | 2019 Sep

REPOSITORIES: biostudies-literature